BLACK WEEKSFlaconcini −15% · kit −10% · resto −5%con il codiceSpedizione gratuita in Germania da 200 €

Questa pagina è stata tradotta automaticamente e può contenere errori. Sei madrelingua? Saremo felici di ricevere il tuo feedback e le tue correzioni.Invia feedback

The Peptide Desk The Peptide Desk
Ostarine (MK-2866), foto del prodotto
SARMs

Ostarine (MK-2866)

SARMs

  • Spedito dalla Germania

Ordine

Prezzo unitario - Spedizione gratuita in Germania da 200 € durante le Black Weeks
  • DHL con tracciamento
  • Imballaggio discreto

4.6 su 5 su Trustpilot73 recensioni

Cercato anche come: Ostarin

In sintesi

Ostarine (MK-2866) in cifre

I dati chiave dalla nostra enciclopedia. Trascina il punto lungo la curva per vedere quanto resta dopo una dose, secondo il calcolo.

Voce completa dell'enciclopedia

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~24 hours

Half-life ~24 hours
After 48 hours: 25 %
Hour 2450 %Hour 4825 %Hour 7212.5 %Hour 1203.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

approx.24hours

Class
SARMnon-steroidal
Use
Oraldaily
Sizes
25 mg1 size in the shop

Non esiste ancora un'analisi di laboratorio per Ostarine (MK-2866). Vota a favoreFallo testare tu, noi paghiamo la metàTutte le analisi di laboratorio

Conoscenze

Tutto su Ostarine (MK-2866)

FAQ

Domande frequenti

Fonti per ogni risposta: voce dell'enciclopedia

Hai ancora una domanda?

Scrivici, il nostro team ti aiuterà.

What is ostarine?

Ostarine, also enobosarm or MK-2866, is a non-steroidal modulator of the androgen receptor (SARM). It was developed against muscle wasting and is meant to act mainly in muscle and bone. It is not approved, the highest stage was phase 3.

What did the study in healthy older adults show?

120 men over 60 and postmenopausal women received placebo or one of four levels for 12 weeks. At the higher level fat-free mass rose by 1.3 kg more than on placebo, fat fell by about 0.6 kg and weight stayed the same. Stair climbing got faster and insulin resistance fell by 27.5 percent. Side effects were as frequent as on placebo.

And in cancer patients?

In a phase 2 trial with 159 cancer patients with weight loss median fat-free mass rose by 1.5 kg (lower level) and 1.0 kg (higher level), on placebo by 0.02 kg. According to the trial the most common serious events were not related to the drug.

What happens to blood lipids and hormones?

HDL cholesterol fell by 17 and 27 percent. The binding protein SHBG fell by 61 percent in men and 80 percent in women. Total testosterone fell in men as well. Free testosterone did not change significantly.

What did the highest study dose show?

A trial in 136 women with advanced breast cancer had two levels, the higher at 18 mg per day. After 24 weeks 29 to 32 percent had a clinical benefit (response or stable disease). Serious side effects caused by the drug occurred in 8 and 16 percent, mainly raised liver enzymes, too much calcium in the blood and fatigue.

Are trials still running?

Yes. As of 26 October 2026 a phase 2 trial with 239 participants is running that tests weight and body function on semaglutide. A first trial on this with 168 participants is completed. Two phase 3 trials in lung cancer ended in 2013.

Confronti

Come si confronta

Correlati

Prodotti correlati